× Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our privacy policy



meta|IO

Evidence base on efficacy and safety of
Immuno-Oncology drugs

Global living systematic review and meta-analysis of RCTs

Latest studies

Modul Cohort 4, 2023

metastatic/advanced - colorectal cancer (mCRC)

atezolizumab plus cometinib

CONTACT-03, 2023

metastatic/advanced RCC (mRCC) - 2nd line (L2)

atezolizumab plus cabozantinib

CheckMate 9DW, 2024

mHCC - 1st line (L1)

nivolumab plus ipilimumab plus SoC

CARES-310, 2023

mHCC - 1st line (L1)

VEGF(R) inhibitor

IMbrave050, 2023

mHCC - (neo)adjuvant (NA)

atezolizumab plus bevacizumab

Wang, 2024

mHCC - (neo)adjuvant (NA)

sintilimab

RATIONALE 301, 2024

mHCC - 1st line (L1)

Tislelizumab

RUBY (part 2), 2024

endometrial cancer

niraparib

MITO END-3, 2023

endometrial cancer

avelumab plus SoC

DUO-E (durvalumab follow by durvalumab and olaparib vs control arms) DUPLICATE, 2023

endometrial cancer

durvalumab plus olaparib plus SoC

RUBY (part 1), 2023

endometrial cancer

dostarlimab plus soC

NRG-GY018_pMMR, 2023

endometrial cancer

pembrolizumab plus SoC

sotorasib NICE ITC Flatiron, 0

metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)

sotorasib

sotorasib NICE ITC 1, 0

metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)

sotorasib

ATEMPT, 2021

breast cancer - adjuvant

trastuzumab emtasine plus endocrine therapy

Bachelot, 2022

breast cancer - adjuvant

everolimus

Drilon (basket), 2018

lung cancer : non small cell (NSCLC)

larotrectinib

LIBRETTO-001 trial (lung cancer), 0

lung cancer : non small cell (NSCLC)

selpercatinib

CodeBreaK 200, 2022

metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)

sotorasib

BRF113928, 0

metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)

trametinib plus dabrafenib

447
treatments 		  367
studies 		  1263
references
This project is supported by H2020 Qualitop, an EU-funded project, Hospices Civils de Lyon and CNRS UMR5558 LBBE.
     

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons